CURIE BIO

Thesis

Curie.Bio is a venture capital firm founded in 2022 in Boston, MA, focusing on the biotechnology and healthcare sectors. They specialize in assisting founders with the discovery and development of new medicines through a hybrid model combining seed venture capital with therapeutics acceleration and drug discovery copiloting. The firm targets early-stage therapeutics companies from concept to clinical trials, including pre-seed, seed, Series A, Series B, and Series C stages. Their investment strategy involves acting as a 'co-pilot' for founders, offering capital, operational support, project management, and access to a network of experts to navigate drug development complexities. Their goal is to help seed-stage companies reach a Series A or equivalent milestone with data packages that attract premium valuations. The Seed Fund advances therapies through preclinical milestones, and the Breakout Fund supports companies through clinical trials. Curie.Bio employs a highly selective investment strategy with a sub-1% acceptance rate. As of early 2025, they manage approximately $1 billion in AUM, with Seed Fund I raising $520 million in February 2023 and the Breakout Fund closing at $380 million in June 2024. They typically invest between $5 million and $15 million per company, with average check sizes from $7 million to $12 million, and a seed-stage check size of $100k to $5M. They have supported the development of over 100 drugs in clinical trials and 44 approved medicines.

Related lists

• Pre-seed Healthcare investors
• Seed-stage Healthcare investors
• Series A Healthcare investors